Skip to content

│European Parliament

Methodology About

GovLensEuropean Legislative Intelligence

Search⌘K

Sign in Enterprise

Parliament

🌍All 🇪🇺EU 🇩🇪DE 🇫🇷FR 🇮🇹IT 🇪🇸ES 🇵🇱PL 🇳🇱NL 🇧🇪BE 🇸🇪SE 🇦🇹AT 🇩🇰DK 🇫🇮FI 🇮🇪IE 🇪🇪EE

Feed Today MEPs Lobbying Countries Budget Insights

Data/Learn/Elections

Topic

Nirmatrelvir

1 procedure tracked

Paxlovid Marketing Objection

2023/2604(RSP)

1st Reading (EP)

GovLens

An independent, open-source transparency platform covering EU and national legislatures across Europe. Built by Trelvio. No advertisers. No sponsors. 100% transparent.

RSS Mastodon GitHub

EU

Feed Today MEPs Lobbying Countries

National

Parliaments Bundestag Assemblée Tweede Kamer

Analyse

Insights Compare Budget Impact Elections

Pro

Enterprise Data & API Embeds Learn

About

About Methodology Privacy Terms Cookies Imprint Transparency

© 2026 GovLensA Trelvio product. EU-sovereign. Open source.Sources: EP Open Data · OEIL · HowTheyVote · EU Transparency Register · National parliament APIs